Emerging evidence supports the use of SGLT2 inhibitors in improving hepatic steatosis, reducing liver fibrosis, and enhancing metabolic parameters in patients with NAFLD and type 2 diabetes [6]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.